A Srinivasan1, L McLaughlin, C Wang, D K Srivastava, D R Shook, W Leung, R T Hayden. 1. Departments of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children's Research Hospital, Memphis, Tennessee, USA; Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
Abstract
INTRODUCTION: Advances in autologous hematopoietic stem cell transplantation (HSCT) over the past 20 years may have had an impact on the morbidity and mortality associated with infections post transplant. PATIENTS AND METHODS: We sought to retrospectively analyze the epidemiology of the first episode of bacterial, fungal, viral, or parasitic infections 0-30 days post transplant in a cohort of 320 children and adolescents who underwent autologous HSCT in a single institution, between 1990 and 2009 for solid tumors or lymphoma, and in 65 children transplanted for acute leukemia during the same period. RESULTS: Infections occurred in 66 (21%) patients with solid tumors or lymphoma. Bacterial infections occurred in 33 (10%) including bacteremia in 23 (7%), and viral infections in 34 (11%) patients. Gram-positive bacterial infections were more prevalent than gram-negative bacterial infections (P = 0.03). Infections caused by fungal or parasitic pathogens were uncommon. The decade when transplant was performed (1990-1999 vs. 2000-2009) had no impact on the incidence of bacterial (P = 0.41) or viral (P = 0.47) infection. Between 1990 and 1999, a total of 60 (92%) children were transplanted for leukemia, and 5 (8%) in the 2000-2009 period (P < 0.0001). Infections occurred in 32 (49%) patients. Bacterial (P = 0.004), candidal (P = 0.003), and herpes simplex viral (P = 0.03) infections were more common in patients transplanted for leukemia. In patients transplanted for leukemia, 3 deaths occurred attributed to infection, all before 2000. CONCLUSION: Changes in epidemiology of infection are likely a result of decline in autologous transplantation for childhood leukemia in the recent era. Autologous transplantation for solid tumors or lymphoma was not associated with mortality from early infections at our institution.
INTRODUCTION: Advances in autologous hematopoietic stem cell transplantation (HSCT) over the past 20 years may have had an impact on the morbidity and mortality associated with infections post transplant. PATIENTS AND METHODS: We sought to retrospectively analyze the epidemiology of the first episode of bacterial, fungal, viral, or parasitic infections 0-30 days post transplant in a cohort of 320 children and adolescents who underwent autologous HSCT in a single institution, between 1990 and 2009 for solid tumors or lymphoma, and in 65 children transplanted for acute leukemia during the same period. RESULTS:Infections occurred in 66 (21%) patients with solid tumors or lymphoma. Bacterial infections occurred in 33 (10%) including bacteremia in 23 (7%), and viral infections in 34 (11%) patients. Gram-positive bacterial infections were more prevalent than gram-negative bacterial infections (P = 0.03). Infections caused by fungal or parasitic pathogens were uncommon. The decade when transplant was performed (1990-1999 vs. 2000-2009) had no impact on the incidence of bacterial (P = 0.41) or viral (P = 0.47) infection. Between 1990 and 1999, a total of 60 (92%) children were transplanted for leukemia, and 5 (8%) in the 2000-2009 period (P < 0.0001). Infections occurred in 32 (49%) patients. Bacterial (P = 0.004), candidal (P = 0.003), and herpes simplex viral (P = 0.03) infections were more common in patients transplanted for leukemia. In patients transplanted for leukemia, 3 deaths occurred attributed to infection, all before 2000. CONCLUSION: Changes in epidemiology of infection are likely a result of decline in autologous transplantation for childhood leukemia in the recent era. Autologous transplantation for solid tumors or lymphoma was not associated with mortality from early infections at our institution.
Authors: B Mascret; D Maraninchi; J A Gastaut; G Novakovitch; G Sebahoun; G Meyer; Y Carcassonne Journal: Lancet Date: 1984-05-26 Impact factor: 79.321
Authors: Daniel Kelly Benjamin; William C Miller; Sherry Bayliff; Lisa Martel; Kenneth A Alexander; Paul Langlie Martin Journal: Pediatr Infect Dis J Date: 2002-03 Impact factor: 2.129
Authors: P Ljungman; K N Ward; B N Crooks; A Parker; R Martino; P J Shaw; L Brinch; M Brune; R De La Camara; A Dekker; K Pauksen; N Russell; A P Schwarer; C Cordonnier Journal: Bone Marrow Transplant Date: 2001-09 Impact factor: 5.483
Authors: S Bilgrami; J Aslanzadeh; J M Feingold; R D Bona; J Clive; D Dorsky; R L Edwards; P J Tutschka Journal: Bone Marrow Transplant Date: 1999-07 Impact factor: 5.483
Authors: Sharon R Lewin; Glenn Heller; Linqi Zhang; Elaine Rodrigues; Eva Skulsky; Marcel R M van den Brink; Trudy N Small; Nancy A Kernan; Richard J O'Reilly; David D Ho; James W Young Journal: Blood Date: 2002-09-15 Impact factor: 22.113
Authors: Ashok Srinivasan; Chong Wang; Deo K Srivastava; Ken Burnette; Jerry L Shenep; Wing Leung; Randall T Hayden Journal: Biol Blood Marrow Transplant Date: 2012-08-23 Impact factor: 5.742
Authors: Holly K Miller; Thomas M Braun; Terri Stillwell; Andrew C Harris; Sung Choi; James Connelly; Daniel Couriel; Steven Goldstein; Carrie L Kitko; John Magenau; Attaphol Pawarode; Pavan Reddy; Mary Riwes; Gregory A Yanik; John E Levine Journal: Biol Blood Marrow Transplant Date: 2016-12-22 Impact factor: 5.742
Authors: Denise Willmer; Stefan K Zöllner; Frieder Schaumburg; Heribert Jürgens; Thomas Lehrnbecher; Andreas H Groll Journal: Cancers (Basel) Date: 2021-04-21 Impact factor: 6.639
Authors: Jane Koo; Stacy Silverman; Brandon Nuechterlein; Amy K Keating; Michael R Verneris; Nicholas K Foreman; Jean M Mulcahy Levy Journal: Bone Marrow Transplant Date: 2019-02-19 Impact factor: 5.483
Authors: Young Bae Choi; Eun Sang Yi; Ji-Man Kang; Ji Won Lee; Keon Hee Yoo; Yae-Jean Kim; Ki Woong Sung; Hong Hoe Koo Journal: PLoS One Date: 2016-09-14 Impact factor: 3.240